Pipeline

Pipeline

Savara has multiple products in various stages of clinical development.

  • A pivotal Phase 3 IMPALA clinical trial of Molgradex to treat patients with PAP is currently ongoing worldwide; patient enrollment is anticipated to be complete in the first quarter of 2018 and top-line results are anticipated in the fourth quarter 2018.
  • A Phase 2a clinical trial of Molgradex to treat patients with antibiotic-resistant NTM lung infection in anticipated to start in early 2018.
  • Savara initiated its pivotal Phase 3 AVAIL Study of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in Q3 2017.
  • Aironite is currently in clinical studies for the treatment of heart failure with preserved ejection fraction (HFpEF).

This page contains Forward Looking Statements, please see Terms of Use

Go to products

Back to Top